Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Cancer
    October 2026
  1. ZHANG BX, Sella T, Zheng Y, Kirkner GJ, et al
    Delays in breast cancer presentation, diagnosis, and treatment in young women.
    Cancer. 2026;132:e70594.
    >> Share

    September 2026
  2. MAZZITELLI N, Star J, Meggett K, Han X, et al
    Prevalence of breast, cervical, and colorectal cancer screening among adults according to disability type and difficulty level, United States, 2021 and 2023.
    Cancer. 2026;132:e70557.
    >> Share

  3. LOO K, Betof AS
    Top advances of the year in autologous cellular therapy in melanoma and solid tumors.
    Cancer. 2026;132:e70612.
    >> Share

  4. PASSERA R, Fabbro E, Zamagni G
    The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.
    Cancer. 2026;132:e70585.
    >> Share

  5. WILLIAMS AD, Weiss A
    Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.
    Cancer. 2026;132:e70587.
    >> Share

    August 2026
  6. HUANG L, Cook LS, Tang MC, Doody DR, et al
    Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor-positive and triple-negative breast cancer patients.
    Cancer. 2026;132:e70562.
    >> Share

  7. LI S, Rojek AE, Shaw R, O'Donoghue C, et al
    Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.
    Cancer. 2026;132:e70526.
    >> Share

  8. ZHOU Y, Liu J, Fu X, Fan J, et al
    Early neural signatures of cancer-related fatigue: A longitudinal magnetic resonance imaging study of cortical micro- and macrostructural changes during breast cancer chemotherapy.
    Cancer. 2026;132:e70558.
    >> Share

    July 2026
  9. GENTRY AL, Sereika SM, Erickson KI, McCall MK, et al
    The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer-related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial.
    Cancer. 2026;132:e70506.
    >> Share

  10. DI COSIMO S, Appierto V, Reduzzi C, De Cecco L, et al
    Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.
    Cancer. 2026;132:e70521.
    >> Share

  11. BERCIANO-GUERRERO MA, Perez-Ruiz E, Soria A, Medina Martinez J, et al
    Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.
    Cancer. 2026;132:e70497.
    >> Share

  12. ARENA L, Alizai Q, Elemosho A, Chatzipanagiotou OP, et al
    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.
    Cancer. 2026;132:e70462.
    >> Share

  13. BAEKER BISPO J, Lee H, Tian J, Jemal A, et al
    Civic engagement and breast cancer screening participation among US citizens.
    Cancer. 2026;132:e70468.
    >> Share

  14. MA VT, Steimle AK, Patel JD, Burkey C, et al
    Updates on intratumoral therapies in melanoma.
    Cancer. 2026;132:e70400.
    >> Share

    June 2026
  15. BEASLEY HK, Shah T, Tinker RJ, Weidner A, et al
    Clinicopathologic characteristics of early-onset breast cancer among unselected young Black women.
    Cancer. 2026;132:e70402.
    >> Share

  16. ARTESE AL, Zhou X, Small BJ, Ahles TA, et al
    Examining bidirectional longitudinal relationships between physical activity and physical function in older breast cancer survivors: The Thinking and Living with Cancer study.
    Cancer. 2026;132:e70366.
    >> Share

  17. LAWRENCE L
    No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.
    Cancer. 2026;132:e70439.
    >> Share

  18. GELLER AC
    Bridging the gap to improve skin cancer prevention practices in childhood cancer survivors.
    Cancer. 2026;132:e70451.
    >> Share

  19. SAKACH EA, Meisel JL, McArthur HL
    Antibody-drug conjugates in breast cancer.
    Cancer. 2026;132 Suppl 1:e70420.
    >> Share

  20. BALLINGER TJ, Zhao F, Jiang G, Shen F, et al
    Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.
    Cancer. 2026;132:e70466.
    >> Share

    May 2026
  21. FENG X, Zhang Y, Gao A, Lu Y, et al
    Breast cancer trends in China and its comparative analysis with group of 20 countries: Projections for 2022-2040.
    Cancer. 2026;132:e70379.
    >> Share

  22. NICOLO E, Bertucci F, Boussen H, Curigliano G, et al
    Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025.
    Cancer. 2026;132:e70447.
    >> Share

  23. NWIGWE I, Tenkasi RV, Desjardins MR, Visvanathan K, et al
    Poverty in the residential and surrounding counties and its impact on mortality in women with breast cancer.
    Cancer. 2026;132:e70414.
    >> Share

    April 2026
  24. MILLER KD, Thomas A, Althouse S, Zang Y, et al
    A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.
    Cancer. 2026;132:e70407.
    >> Share

  25. CHEN I
    Design-analysis mismatch in the analysis of longitudinal HER2 data in breast cancer.
    Cancer. 2026;132:e70383.
    >> Share

  26. NIGG C, Zarkovic M, Jorger P, Tinner EME, et al
    Sun protection and skin cancer screening after childhood cancer-A report from the Swiss Childhood Cancer Survivor Study.
    Cancer. 2026;132:e70364.
    >> Share

  27. KISHIMOTO K, Nakata K, Kato MS, Ikawa T, et al
    Increasing incidence and changing distribution of primary cancers in therapy-related acute myeloid leukemia: A population-based study in Osaka, Japan, 1990-2020.
    Cancer. 2026;132:e70316.
    >> Share

    March 2026
  28. BHIMANI J, O'Connell K, Blinder VS, Burganowski R, et al
    The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.
    Cancer. 2026;132:e70318.
    >> Share

  29. DESSINIOTI C, Stratigos A
    Neoadjuvant systemic immunotherapy for skin cancers.
    Cancer. 2026;132:e70354.
    >> Share

  30. FIELDS BC, Traweek RS, Jiang K, Witt RG, et al
    High dietary fiber is associated with improved outcomes in patients with melanoma and sarcoma treated with immunotherapy regardless of gut microbiome dysbiosis and social vulnerability.
    Cancer. 2026;132:e70335.
    >> Share


  31. Correction to "Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele".
    Cancer. 2026;132:e70350.
    >> Share

  32. MONROY-IGLESIAS MJ, O'Connell K, Bhimani J, Blinder VS, et al
    Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.
    Cancer. 2026;132:e70294.
    >> Share

  33. REESE JB, Zimmaro LA, Sorice KA, Zhang L, et al
    Efficacy of a sexual quality of life intervention for couples facing metastatic breast cancer: Results of a randomized controlled trial.
    Cancer. 2026;132:e70334.
    >> Share

    February 2026
  34. ZHANG L, Zheng A, Cao Y, Zhang T, et al
    Sentinel lymph node biopsy using dye alone in patients with initial clinical N1 breast cancer receiving neoadjuvant therapy: A multicenter diagnostic trial (Northern Breast Cancer Collaboration Group NBCG-002).
    Cancer. 2026;132:e70298.
    >> Share

  35. NIERENBERG TC, Thomas SM, Reason EH, Modell Parrish KJ, et al
    Breast cancer staging for patients with "low-risk" disease: Are they all the same?
    Cancer. 2026;132:e70305.
    >> Share

  36. SCHUMACHER JR, Hanlon BM, Zahrieh D, Rathouz PJ, et al
    Impact of a web-based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD).
    Cancer. 2026;132:e70314.
    >> Share

  37. LIMA SM, Palermo TM, Tian L, Lee FF, et al
    The effect of time on associations between historical redlining and breast cancer survival.
    Cancer. 2026;132:e70230.
    >> Share

  38. SCHERMERHORN SMV, Vore E, Bondoc AJ, Lautz TB, et al
    Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study.
    Cancer. 2026;132:e70274.
    >> Share

  39. LIPSCOMB J, Kimmick GG, Wilson JF, Currey A, et al
    Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.
    Cancer. 2026;132:e70267.
    >> Share

  40. ZAKHARIA Y, Kim D, Freesmeier M, Frees M, et al
    A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
    Cancer. 2026;132:e70326.
    >> Share

  41. DILEO M, Oglesby S, Leung CH, Pauken KE, et al
    Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.
    Cancer. 2026;132:e70262.
    >> Share

  42. QIU Y, Wu L, Cai W, Chen M, et al
    The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study.
    Cancer. 2026;132:e70269.
    >> Share

  43. MA Y, Li X, Jiang Y, Xiao L, et al
    The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis.
    Cancer. 2026;132:e70268.
    >> Share

  44. LAWRENCE L
    Nine-year data show sustained benefit of nivolumab in patients with high-risk resected melanoma.
    Cancer. 2026;132:e70234.
    >> Share

    January 2026
  45. ZHAO J, Graetz I, Howard D, Yabroff KR, et al
    Federal and state policies regulating short-term limited-duration insurance plans and timely cancer treatment initiation.
    Cancer. 2026;132:e70190.
    >> Share

  46. CHOI HL, Kim B, Mark Park YM, Yoo JE, et al
    Metabolic obesity phenotypes and breast cancer risk before and after menopause: A nationwide cohort study in South Korea.
    Cancer. 2026;132:e70244.
    >> Share

  47. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    >> Share

    December 2025
  48. ALLER A, Zhu S, Lyon L, Habel LA, et al
    Is age just a number? Oncotype DX testing and chemotherapy use in the post-TAILORx era.
    Cancer. 2025;131:e70218.
    >> Share

  49. ARGUELLO-TOMAS M, Lynton-Pons E, Albiol N, Lopez-Ferrer A, et al
    Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia.
    Cancer. 2025;131:e70216.
    >> Share

  50. LUIJENDIJK MJ, Lee Meeuw Kjoe PR, Wortelboer N, van Ommen-Nijhof A, et al
    Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer.
    Cancer. 2025;131:e70212.
    >> Share

  51. MOUNA BM, Batra A, Sharma V, Kataria B, et al
    Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: A prospective phase 2 open-label randomized controlled trial (McBETH).
    Cancer. 2025;131:e70205.
    >> Share


  52. Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".
    Cancer. 2025;131:e70188.
    >> Share

  53. MULLINS MA, Wang T, Furgal A, Hamilton AS, et al
    Changes in patient-reported primary care engagement in and communication about survivorship care from initial breast cancer treatment to longer-term survivorship.
    Cancer. 2025;131:e70181.
    >> Share

    November 2025
  54. KORIC A, Jiang S, Liu Y, Colditz GA, et al
    Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis.
    Cancer. 2025;131:e70164.
    >> Share

  55. MAHMOUD MA, Edmonds CE, Barufaldi B, Nguyen A, et al
    Racial differences in quantitative background parenchymal enhancement on breast magnetic resonance imaging.
    Cancer. 2025;131:e70174.
    >> Share

  56. FITCH KC, Yang JC, Ryan ES, Monuszko KA, et al
    Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer.
    Cancer. 2025;131:e70148.
    >> Share

  57. BARBER LE, Maliniak ML, Miller-Kleinhenz JM, Moubadder L, et al
    Understanding the role of neighborhood deprivation in racial disparities in triple-negative breast cancer.
    Cancer. 2025;131:e70138.
    >> Share

    October 2025
  58. GIAQUINTO AN, Freedman RA, Newman LA, Jemal A, et al
    Lobular breast cancer statistics, 2025.
    Cancer. 2025;131:e70061.
    >> Share

  59. BOWER JE, Radin A, Ganz PA, Irwin MR, et al
    Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination.
    Cancer. 2025;131:e70038.
    >> Share

  60. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    >> Share

  61. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
    Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
    Cancer. 2025;131:e70073.
    >> Share

  62. RIBI K, Cole BF, Fleming GF, Walley BA, et al
    Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
    Cancer. 2025;131:e70094.
    >> Share

  63. COLAES R, Schroyen G, Radwan A, Gavrila Laic RA, et al
    Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition.
    Cancer. 2025;131:e70095.
    >> Share

  64. SHAFFER KM, Daniel KE, Wiseman KP, Ritterband LM, et al
    Prospective associations between sleep quality and sexual satisfaction in distressed breast cancer survivors: Secondary analysis from the Apps Reaching Cancer Survivors randomized trial.
    Cancer. 2025;131:e70093.
    >> Share

    September 2025
  65. ROOHANI S, Griffin AM, Liu ZA, Catton CN, et al
    Preoperative intensity-modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue.
    Cancer. 2025;131:e70049.
    >> Share

  66. CHEN M, Lin Z, Chen X, Zhang J, et al
    Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.
    Cancer. 2025;131:e70047.
    >> Share

    August 2025
  67. MILHEM MM, Zakharia Y, Davar D, Buchbinder EI, et al
    Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
    Cancer. 2025;131:e70022.
    >> Share

    July 2025
  68. FONTVIEILLE E, Jansana A, Peruchet-Noray L, Cordova R, et al
    Body mass index and breast cancer risk among postmenopausal women with and without cardiometabolic diseases: Findings from two prospective cohort studies in Europe.
    Cancer. 2025;131:e35911.
    >> Share

  69. MENZIES AM, Salman P, Frontera OA, Pook D, et al
    Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
    Cancer. 2025;131:e35962.
    >> Share

  70. KIM Y, Doma V, Cakir U, Kuras M, et al
    Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.
    Cancer. 2025;131:e35897.
    >> Share

    June 2025
  71. FUMAGALLI IA, Warner ET, Llanos AAM, Quesenberry CP, et al
    Racial and ethnic variation in body composition and prognosis of nonmetastatic breast cancer.
    Cancer. 2025;131:e35926.
    >> Share

  72. WANIS KN, Mitchell MP, Giordano SH, Litton JK, et al
    Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers.
    Cancer. 2025;131:e35910.
    >> Share

  73. AUBUCHON KE, Galvan CJC, Duron Y, Sampayo I, et al
    Randomized trial of a community-based, culturally tailored intervention: High engagement among Latina breast cancer survivors.
    Cancer. 2025;131:e35842.
    >> Share

  74. TRINCONI CUNHA M, Wallace N, Porceddu S, Ferrarotto R, et al
    Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.
    Cancer. 2025;131:e35920.
    >> Share

  75. NIERENGARTEN MB
    New standard of care for patients with asymptomatic brain metastases from melanoma.
    Cancer. 2025;131:e35885.
    >> Share

    May 2025
  76. LEE MS, Thomas SM, Louie AD, Rosenberger LH, et al
    Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.
    Cancer. 2025;131:e35891.
    >> Share

  77. ZHANG H, Charlton BM, Schnarrs PW, Trentham-Dietz A, et al
    Mammography screening and risk factor prevalence by sexual identity: A comparison of two national surveys.
    Cancer. 2025;131:e35852.
    >> Share

  78. YEN TWF, Nattinger AB, Bickell NA, Schymura MJ, et al
    Does regionalization of initial breast cancer care delay time to surgery?
    Cancer. 2025;131:e35895.
    >> Share

  79. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    >> Share

  80. ZOPE M, Sullivan R, Gutnik L
    Fragmented care and misaligned incentives of stakeholders in breast cancer care for the uninsured in the United States.
    Cancer. 2025;131:e35878.
    >> Share

  81. PEARCE A, Carter S, Frazer HM, Houssami N, et al
    Implementing artificial intelligence in breast cancer screening: Women's preferences.
    Cancer. 2025;131:e35859.
    >> Share

  82. SIMON LH, Saviers-Steiger C, Dunston ER, Galyean P, et al
    Feasibility and acceptability of the Comprehensive Oncology Rehabilitation and Exercise (CORE) clinical workflow algorithm in patients with newly diagnosed stage I-III breast cancer who undergo surgery as first-line treatment.
    Cancer. 2025;131:e35798.
    >> Share

  83. CHEN MF, Postow MA
    Top advances of the year: Neoadjuvant immunotherapy in melanoma.
    Cancer. 2025;131:e35877.
    >> Share

  84. NIERENGARTEN MB
    Two-fold increased risk of melanoma in childhood cancer survivors.
    Cancer. 2025;131:e35828.
    >> Share

    April 2025
  85. ZEINOMAR N, Perlstein M, Qin B, Iyer HS, et al
    Associations between experiences of discrimination and quality of life in Black breast cancer survivors.
    Cancer. 2025;131:e35836.
    >> Share

  86. PALESH O, Braun SE, Truong T, Hong S, et al
    Natural trajectory subclasses of cognitive impairment in breast cancer patients experiencing insomnia.
    Cancer. 2025;131:e35816.
    >> Share

  87. GRAFF SL, Tolaney SM, Hart LL, Razavi P, et al
    Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
    Cancer. 2025;131:e35817.
    >> Share

    March 2025
  88. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    >> Share

  89. PATEL RB, Sheng T, Diniz MA, Sparano JA, et al
    Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis.
    Cancer. 2025;131:e35771.
    >> Share

  90. NIERENGARTEN MB
    Immune checkpoint inhibitors increase the risk of psoriasis.
    Cancer. 2025;131:e35753.
    >> Share

    February 2025
  91. MAZOR M, Lin JJ, Smith C, Rosa WE, et al
    Community-engaged adaptation of ACCESS: A navigator-led early palliative care intervention for Black and Latina women with advanced breast cancer.
    Cancer. 2025;131:e35745.
    >> Share

  92. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    >> Share

  93. WAKS AG, Tarantino P, Chen EL, Freedman RA, et al
    Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019.
    Cancer. 2025;131:e35729.
    >> Share

  94. MARCOTTE LM, Khor S, Reddy A, Morenz A, et al
    An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system.
    Cancer. 2025;131:e35734.
    >> Share

    January 2025
  95. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    >> Share

  96. RAJABIUN S, Cabral HJ, Chen CA, Lloyd-Travaglini C, et al
    Cost and activity analysis for a citywide patient navigation intervention to engage underserved patients in breast cancer treatment: Findings from the Translating Research Into Practice study.
    Cancer. 2025;131:e35671.
    >> Share

  97. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    >> Share

  98. BONTEMPS-JONES JE, McCullough LE, Kirkland EG, Teras LR, et al
    Beyond Tuskegee: A contemporary qualitative assessment of barriers to research participation among Black women.
    Cancer. 2025;131:e35648.
    >> Share

  99. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    >> Share

  100. SHIN DS, Ryu JM, Lee SK, Yu J, et al
    Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Cancer. 2025;131:e35567.
    >> Share

  101. TAN NQP, Ma GX, Maxwell AE, Brown RL, et al
    The impact of a small-group mammography video discussion on promoting screening uptake among nonadherent Chinese American immigrant women: A randomized controlled trial.
    Cancer. 2025;131:e35524.
    >> Share

  102. WINER LK, Akumuo R, Fredette JD, Deng M, et al
    Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi-institutional collaborative.
    Cancer. 2025;131:e35468.
    >> Share

    December 2024
  103. LIU KX, Shin KY, Thakuria M, Schoenfeld JD, et al
    Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence.
    Cancer. 2024;130:4267-4275.
    >> Share

  104. DANIELSEN JT, Zachariae R, Schmidt H, Kallehauge JF, et al
    Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35683.
    >> Share

  105. LE BRUN IC, Dalle S, Mortier L, Dereure O, et al
    Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35679.
    >> Share

  106. REESE JB, Lepore SJ, Sorice KA, Zimmaro LA, et al
    Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35685.
    >> Share

    November 2024
  107. YAROSH RA, Nichols HB, Wang Q, Hirschey R, et al
    Patient-reported persistent lymphedema and peripheral neuropathy among long-term breast cancer survivors in the Carolina Breast Cancer Study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35650.
    >> Share

  108. DESAI P, Zhou Y, Grenet J, Handelman SK, et al
    Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
    Cancer. 2024;130:3879-3887.
    >> Share

  109. DEPALO DK, Dugan MM, Naqvi SMH, Ollila DW, et al
    A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35636.
    >> Share

    October 2024
  110. MUSLUMANOGLU M, Cabioglu N, Igci A, Karanlik H, et al
    Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35610.
    >> Share

  111. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    >> Share

  112. BRUNET J, Sharma S, Zadravec K, Taljaard M, et al
    Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE): A randomized controlled trial.
    Cancer. 2024 Oct 21. doi: 10.1002/cncr.35540.
    >> Share

  113. GARG N, Thorat MA
    A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design.
    Cancer. 2024;130:3549-3550.
    >> Share

  114. ZHENG QJ, Xu L, Fan ZQ
    Reply to "A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design".
    Cancer. 2024;130:3551-3552.
    >> Share

  115. TIN TIN S, Smith-Byrne K, Ferrari P, Rinaldi S, et al
    Alcohol intake and endogenous sex hormones in women: Meta-analysis of cohort studies and Mendelian randomization.
    Cancer. 2024;130:3375-3386.
    >> Share

  116. SHI KS, Han X, Star J, Zhao J, et al
    Association of health insurance coverage disruptions and breast and colorectal cancer screening.
    Cancer. 2024 Oct 1. doi: 10.1002/cncr.35584.
    >> Share

    September 2024
  117. LAO CD, Moon J, Ma VT, Fruehauf JP, et al
    Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587.
    >> Share

  118. SELLA T, Sorouri K, Rosenberg SM, Loucks M, et al
    Breastfeeding experiences among young breast cancer survivors: A survey study.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35585.
    >> Share

  119. IYENGAR NM, Scott JM, Lee J, Lavery JA, et al
    Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35575.
    >> Share

  120. WANG X, Shang Y, Zhang J, Liu J, et al
    Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35581.
    >> Share

  121. ELSHAFIE S, Trivedi R, Villa-Zapata LA, Tackett RL, et al
    Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis.
    Cancer. 2024 Sep 5. doi: 10.1002/cncr.35550.
    >> Share

  122. LI R, Hua M, Li J, Chen W, et al
    The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis.
    Cancer. 2024;130:2968-2977.
    >> Share

  123. XU C, Chen Z, Xia Y, Shi Y, et al
    Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.
    Cancer. 2024;130.
    >> Share

    August 2024
  124. PARK KU, Lipsitz S, Dominici LS, Lynce F, et al
    Generative artificial intelligence as a source of breast cancer information for patients: Proceed with caution.
    Cancer. 2024 Aug 30. doi: 10.1002/cncr.35521.
    >> Share

  125. PLICHTA JK, Thomas SM, Chanenchuk TC, Chan K, et al
    Comparison of incident breast cancer cases in the largest national US tumor registries.
    Cancer. 2024 Aug 18. doi: 10.1002/cncr.35525.
    >> Share

  126. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    >> Share

  127. NIERENGARTEN MB
    Inequities in breast cancer from prevention through supportive care.
    Cancer. 2024;130:2570.
    >> Share

  128. MILLER DM, Shalhout SZ, Wright KM, Miller MA, et al
    The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study.
    Cancer. 2024;130:2670-2682.
    >> Share

    July 2024
  129. ROZEMAN EA, Luke JJ
    The emergence of neoadjuvant immune-over BRAF therapy in melanoma.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35490.
    >> Share

  130. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    >> Share

    June 2024
  131. REINER AS, Knight JA, John EM, Lynch CF, et al
    Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window.
    Cancer. 2024 Jun 28. doi: 10.1002/cncr.35459.
    >> Share

  132. LU W, Giobbie-Hurder A, Tanasijevic A, Kassis SB, et al
    Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.
    Cancer. 2024 Jun 24. doi: 10.1002/cncr.35374.
    >> Share

  133. DENT S, Tumlinson R, Guha A, Moore H, et al
    Breast cancer risk reduction: Beyond pharmacologic intervention.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35442.
    >> Share

  134. CHUNG HC, Saada-Bouzid E, Longo F, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35387.
    >> Share

  135. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    >> Share

  136. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    >> Share

  137. SELMOUNI F, Bendahhou K, Sauvaget C, Abahssain H, et al
    Impact of CBE-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35419.
    >> Share

    May 2024
  138. BELAU MH, Jung L, Maurer T, Obi N, et al
    Social relationships and their impact on health-related quality of life in a long-term breast cancer survivor cohort.
    Cancer. 2024 May 17. doi: 10.1002/cncr.35364.
    >> Share

  139. SCHETTINI F, Blondeaux E, Molinelli C, Bas R, et al
    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35323.
    >> Share

  140. CHLEBOWSKI RT, Aragaki AK, Pan K, Simon MS, et al
    Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
    Cancer. 2024 May 13. doi: 10.1002/cncr.35318.
    >> Share

  141. HOVHANNISYAN M, Zemankova P, Nehasil P, Matejkova K, et al
    Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35337.
    >> Share

  142. GUO H, Malone KE, Heckbert SR, Li CI, et al
    Statin use and risks of breast cancer recurrence and mortality.
    Cancer. 2024 May 6. doi: 10.1002/cncr.35362.
    >> Share

    April 2024
  143. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    >> Share

  144. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    >> Share

  145. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    >> Share

  146. BERNSTEIN-MOLHO R, Shhada NA, Laitman Y, Netzer I, et al
    Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed >/=50 years.
    Cancer. 2024 Apr 17. doi: 10.1002/cncr.35329.
    >> Share

  147. VANNIER AGL, Dhungana A, Zhao F, Chen N, et al
    Validation of the RSClin risk calculator in the National Cancer Data Base.
    Cancer. 2024;130:1210-1220.
    >> Share

  148. NIERENGARTEN MB
    Routine estradiol testing recommended for women at high risk of breast cancer.
    Cancer. 2024;130:1014.
    >> Share

  149. NIERENGARTEN MB
    Cardiotoxicity of breast cancer drugs requires additional monitoring.
    Cancer. 2024;130:1013-1014.
    >> Share

  150. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
    Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
    Cancer. 2024;130:1041-1051.
    >> Share

    March 2024
  151. WANG X, O'Regan RM
    Breast cancer therapy in China: Introducing the Special Collection.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
    >> Share

  152. NIERENGARTEN MB
    FDA approves capivasertib with fulvestrant for breast cancer.
    Cancer. 2024;130:835-836.
    >> Share

  153. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    >> Share

  154. PUKLIN LS, Ferrucci LM, Harrigan M, McGowan C, et al
    Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35280.
    >> Share

  155. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    >> Share

    February 2024
  156. HOU X, Li X, Han Y, Xu H, et al
    Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
    >> Share

  157. LI X, Luo S, Fu W, Huang M, et al
    Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35228.
    >> Share

  158. NGUYEN SM, Tran HTT, Long J, Shrubsole MJ, et al
    Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.
    Cancer. 2024 Feb 6. doi: 10.1002/cncr.35229.
    >> Share

    January 2024
  159. XIONG W, Xu T, Liu X, Zhang L, et al
    Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
    >> Share

  160. QU F, Lu R, Liu Q, Wu X, et al
    Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
    >> Share

  161. SMITH KL, Zhao F, Mayer IA, Tevaarwerk AJ, et al
    Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35187.
    >> Share

  162. WANG J, Xia YC, Tian BX, Li JT, et al
    Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
    Cancer. 2024 Jan 13. doi: 10.1002/cncr.35176.
    >> Share

  163. ZHOU X, Liu M, Zheng Z, Cao X, et al
    Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population-based study.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35166.
    >> Share

  164. LIANG X, Zhang L, Gui X, Di L, et al
    Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35174.
    >> Share

  165. AGGARWAL A, Han L, Lewis D, Costigan J, et al
    Association of travel time, patient characteristics, and hospital quality with patient mobility for breast cancer surgery: A national population-based study.
    Cancer. 2024 Jan 8. doi: 10.1002/cncr.35153.
    >> Share

  166. SATHISHKUMAR K, Sankarapillai J, Mathew A, Nair RA, et al
    Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme.
    Cancer. 2024 Jan 6. doi: 10.1002/cncr.35188.
    >> Share

  167. BHATT R, van den Hout A, Antoniou AC, Shah M, et al
    Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors.
    Cancer. 2024 Jan 4. doi: 10.1002/cncr.35183.
    >> Share

    December 2023
  168. AKKOC MUSTAFAYEV FN, Shukla MA, Lanier A, Milton DR, et al
    Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35159.
    >> Share

  169. ZHANG S, Guo L, Zhang Z, Liu X, et al
    Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35142.
    >> Share

    November 2023
  170. WILLIAMS AD, Ruth K, Shaikh SS, Vasigh M, et al
    Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35136.
    >> Share

  171. YU T, Lu Y, Fang J, Jiang X, et al
    Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Cancer. 2023 Nov 11. doi: 10.1002/cncr.35096.
    >> Share

  172. LI J, Jiang Z
    Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects.
    Cancer. 2023 Nov 3. doi: 10.1002/cncr.35093.
    >> Share

  173. ZHU J, Wang L, Gong W, Li X, et al
    Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study.
    Cancer. 2023 Nov 2. doi: 10.1002/cncr.35095.
    >> Share

    July 2023
  174. GEFFEN SR, Poteat T, Dean LT, Malone J, et al
    Engaging black sexual minority women in breast cancer research: Lessons in community partnerships.
    Cancer. 2023 Jul 25. doi: 10.1002/cncr.34960.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016